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Medical decisions about type of primary surgery and adjuvant
therapy in breast cancer are influenced by a patient’s expected
prognosis. Reduction in death from breast cancer is the ultimate
goal in both preventive and therapeutic strategies. We have used
competing risk analyses (Fish et al, 1998) to investigate the effects
of surgical procedure, adjuvant therapy and traditional prognostic
factors for breast cancer (age, tumour size, nodal status, ER and
PgR) on whether a patient will die from breast cancer or some
other cause, as well as the time to death.
The effects of factors on recurrence at local, regional or distant
sites are usually assessed separately. In part, one might view local
recurrence as being controllable with the modalities of surgery and
radiotherapy. Regional and distant metastases are more commonly
viewed as potential risk for breast cancer death.
In the context of recurrence, Gelman et al (1990) discussed
reasons why, even in a randomized clinical trial, the assessment of
treatment effects may not be straightforward for recurrence end-
point(s). The standard statistical assumption of independence of
end-points such as local and distant recurrence may be violated to
such an extent that a competing risks analysis is better used under
such circumstances. For instance, analytic assumptions about
unobtainable recurrence information could lead to it being impos-
sible to ascertain precisely whether adjuvant radiation was a bene-
ficial adjunct for the local control of breast cancer.
Veronesi et al (1995) demonstrated with competing risks
analyses of a large cohort of 2233 patients, all of whom had
received the breast conserving procedure of quadrantectomy, that
there was a significant lack of independence between the develop-
ment of local and distant recurrence; patients who developed a
local recurrence had a hazard of relapsing from distant metastases
that is 4.62 times greater than that for patients who did not develop
a local recurrence. Further, they showed that factors could differ-
entially affect the development of local and distant recurrence.
The analysis background for a competing risks assessment may
be found elsewhere: Allison (1995) is an introductory text while
Kalbfleisch and Prentice (1980) and Cox and Oakes (1984)
contain more advanced statistical presentations. The particular
hierarchical approach employed in this paper is illustrated for lung
cancer data in Lagakos (1978).
We report here the results of competing risks analyses to assess
simultaneously the effects of traditional factors on recurrence at
local, regional and distant sites for a cohort of primary breast
cancer patients, many of whom received minimal surgery.
Additionally, most patients did not receive adjuvant therapy; this
was particularly true for the elderly.
MATERIALS AND METHODS
Patients
All the patients assessed and followed were from the surgical prac-
tice of EBF. They presented with unilateral primary invasive
breast cancer, stage 1–3, with no previous history of carcinoma,
except possibly in situ cervix or non-melanoma skin. The cohort of
678 consecutive patients meeting these criteria were accrued
between 1971 and 1990. The numbers of patients operated on by
calendar year, and type of surgery have been reported elsewhere
(Fish et al, 1998). The follow-up to 1995 was complete for 91% of
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patients. The median follow-up for those alive was 8.2 years for all
patients, and 7.7 years for those over 65 years of age.
Surgical procedure
In all, 366 patients received a lumpectomy; 119 were clinically
node negative (Nx) and elected to have no axillary dissection,
while 247 had an axillary dissection and were designated to be N–
or N+. Lumpectomy is defined as a surgical attempt to remove the
entire tumour and enough surrounding tissue to ensure the exci-
sion was adequate. Usually, about 2 cm of normal breast tissue
was removed in each direction and, nearly always, the underlying
pectoralis fascia. If the tumour was near the skin, a thin ellipse of
skin was taken to indicate the anterior margin. The specimens
were inked and they were examined by a pathologist in gross at the
time of surgery, and on paraffin sections to assess the borders.
A mastectomy was performed on 312 patients (simple or subcu-
taneous, 50 patients; modified radical, 262 patients). The regional
recurrence rates for the mastectomy patients were 0% (0/112) for
N–, 4% (2/50) for Nx, and 1% (2/150) for N+ (P = 0.11); the
corresponding data for those ³ 65 years of age is 0% (0/32) for N–,
4% (1/26) for Nx, and 3% (1/30) for N+ (P = 0.52).
Effects of covariates
The event of interest was the first recurrence which was ascertained
to be local, regional or distant. A patient’s time on study was the
time until first recurrence (event), time until death from another
Table 1 First recurrence by age group
Patient group
No.
Type of first recurrence
First
of cases Local Regional Distant recurrence P-valuea
< 65 471 77 (16%) 16 (3%) 81 (17%) 174 (37%)
0.28
³ 65 207 25 (12%) 5 (2%) 27 (13%) 57 (28%)
aBased on Wilcoxon (Peto–Prentice) test statistic.
Table 2 First recurrence by factor subgroup
Factor
No.
Type of first recurrence
First
P-valuea of cases Local Regional Distant recurrence
Age
≤ 49 197 40 (20%) 3 (2%) 29 (15%) 72 (37%)
50–64 274 37 (14%) 13 (5%) 52 (19%) 102 (37%) 0.51
³ 65 207 25 (12%) 5 (2%) 27 (13%) 57 (28%)
Tumour size (cm)
≤ 2 363 46 (13%) 11 (3%) 46 (13%) 103 (28%)
[2–5] 266 48 (18%) 8 (3%) 48 (18%) 104 (39%) < 0.001
> 5 32 5 (16%) 1 (3%) 10 (31%) 16 (50%)
Nodal status
N– 251 24 (10%) 0 (0%) 32 (13%) 56 (22%)
Nx 169 33 (20%) 13 (8%) 15 (9%) 61 (36%) < 0.001
N+ 258 45 (17%) 8 (3%) 61 (24%) 114 (44%)
ER
< 10 fmol/mg protein 115 22 (19%) 4 (3%) 15 (13%) 41 (36%)
0.21 ³ 10 fmol/mg protein 472 68 (14%) 14 (3%) 83 (18%) 165 (35%)
PgR
< 10 fmol/mg protein 90 16 (18%) 1 (1%) 13 (14%) 30 (33%)
0.38 ³ 10 fmol/mg protein 353 54 (15%) 9 (3%) 57 (16%) 120 (34%)
Adjuvant radiation
No 517 91 (18%) 18 (3%) 78 (15%) 187 (36%)
0.12 Yes 159 11 (7%) 3 (2%) 30 (19%) 44 (28%)
Adjuvant chemotherapy
No 572 87 (15%) 19 (3%) 86 (15%) 192 (34%)
0.57 Yes 104 15 (14%) 2 (2%) 22 (21%) 39 (38%)
Adjuvant hormones
No 556 91 (16%) 19 (3%) 81 (15%) 191 (34%)
0.73 Yes 118 11 (9%) 2 (2%) 27 (23%) 40 (34%)
aBased on Wilcoxon (Peto–Prentice) test statistic (Prentice and Marek, 1979).1510 JW Chapman et al
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cause (patient was ‘censored’ at time of death), or length of follow-
up (patient was alive and well – ‘censored’). The date for first
recurrence always preceded a patient’s death from breast cancer.
We investigated the multivariate effects of the covariates on
recurrence in the following units: age (in years), tumour size (cm),
nodal status (N–, Nx, N+), oestrogen and progesterone receptors
(ER and PgR; fmol/mg protein), adjuvant radiotherapy (no, yes),
adjuvant hormonal therapy (no, yes), and adjuvant chemotherapy
(no, yes) on time to first recurrence. With the exception of nodal
status where Nx patients are known to be clinically node negative,
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Figure 1 Disease-free survival by tumour size
Figure 2 Disease-free survival by nodal statusCompeting risks analyses for recurrence 1511
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patients with missing data for any factor were not included in the
multivariate analyses. Owing to the large amount of missing data
for PgR, analyses were performed both with and without PgR; the
only results reported here are those with PgR, since it was included
in the best models. The use of the larger data set, obtained by
excluding PgR, did not substantially alter the competing risks
results for other factors.
Univariate Kaplan–Meier plots were made, and the Wilcoxon
(Peto–Prentice) test statistic (Prentice and Marek, 1979) was used
to assess the univariate effects for all ages of patients, and for
those patients ³ 65 years of age. A split was made at age 65 due to
differences in treatment recommendations based on likely aggres-
siveness of breast cancer, ability to mammographically detect
recurrence, and overall life expectancy.
We investigated the multivariate effects of the covariates with
Cox and log-normal (Kalbfleisch and Prentice, 1980) forward
stepwise regressions, performed for the whole patient group and
those ³ 65 years of age. The model improvement for the addition
of k factors to the model was assessed with the likelihood ratio
criterion; where R is the likelihood ratio, – 2 log R ~ X2
(k) under the
assumption that the k factors are not associated with time to first
recurrence. A factor was added if P ≤ 0.05; all factors maintained
significance once they were included in the model.
Competing risks analyses were completed using the Dynamic 7
PC version of Biomedical Data Package (BMDP, 1993). A log-
normal model was used to assess the effects of the covariates on
type of first recurrence (local, regional, distant) and time to first
recurrence for the whole patient group, as well as for those ³ 65
years of age. There are three hierarchical hypotheses tested for
each covariate: (1) the covariate has no effect on type of first
recurrence and time to first recurrence; (2) the covariate has no
effect on type of first recurrence; (3) the covariate has no effect on
time of first recurrence, given it has no effect on type of first
recurrence. A result was significant if P ≤ 0.05.
RESULTS
Table 1 indicates that there was a similar pattern of first recurrence
by age group (P = 0.28): 16% local recurrence for those < 65 years
vs. 12% for those ³ 65 years; with corresponding regional recur-
rence of 3% and 2% respectively; and respective distant recur-
rence of 17% and 13%.
Table 2 summarizes the first recurrence rates for patients by
subgroup classifications of the investigational factors. Patients
with larger tumour sizes and lymph node metastases were more
likely to have experienced a first recurrence (P < 0.001, in each
instance). No other factor exhibited significant univariate differ-
ences in recurrence by factor subgroups. Figures 1 and 2 are the
disease-free survival plots for tumour size and nodal status.
The same factors were included in the best stepwise models
using the Cox (Table 3) and log-normal model-types. For all
patients, tumour size and nodal status had negative associations
with time to first recurrence (of any type) while adjuvant
chemotherapy, age, adjuvant radiation and PgR had positive asso-
ciations. For patients ³ 65 years of age, the only factors included in
the stepwise multivariate models were nodal status and tumour
size which had negative associations with time to first recurrence.
In the competing risks analyses on the data for all ages of
patients, there was significant evidence (P ≤ 0.05) that the factors
adjuvant radiation, age, nodal status, tumour size and adjuvant
chemotherapy were associated with type of first recurrence or time
to first recurrence; the P-value for PgR was 0.24. The covariate
adjuvant radiation had a significant effect (P < 0.001) on type of
first recurrence (Figure 3). It was associated with a longer disease-
free period before local recurrence, but had no significant effect on
regional or distant recurrence. The other factors (age, nodal status,
tumour size and adjuvant chemotherapy) did not have significantly
different effects on type of recurrence, but were associated with
significant effects on time to first recurrence (Figure 4). Older age,
pathologically negative nodes, smaller tumours and receiving
adjuvant chemotherapy were associated with longer disease-free
periods.
In the competing risks analyses for patients ³ 65 years of age,
there were only two factors with significant evidence of associa-
tion with type or time to first recurrence: nodal status and tumour
size. Both of these factors were associated with time to recurrence
(Figure 4); negative nodes and smaller tumours were associated
with longer disease-free periods.
Table 3 Cox stepwise regression for first recurrence of any type
Factors in best models – b ˆ/s.e.a P-value
All patients
Tumour size – 4.28 < 0.001
Nodal status – 4.36 < 0.001
Adjuvant chemotherapy 3.16 0.002
Age 3.00 0.003
Adjuvant radiotherapy 2.56 0.01
PgR 1.75 0.08b
Patients ≤ 65 years of age
Nodal status – 2.97 0.003
Tumour size – 2.73 0.01
aA positive/negative coefficient suggests a positive/negative effect for larger
values of the factor on a type of recurrence. b – 2 log RP -value for addition of
factor to model = 0.05.
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Figure 3 Covariates with significant effects on type of first recurrence – all
ages. The standardized coefficients, ˆ b/s.e., permit a comparison of the
potential effects across factors. A positive/negative coefficient suggests a
positive/negative effect for larger values of the factor on a type of recurrence1512 JW Chapman et al
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DISCUSSION
Competing risks analyses were developed to assess jointly length
of survival for people who have disease-specific recurrence, or die,
in a variety of ways (Proschan and Serfling, 1974; Kalbfleisch and
Prentice, 1980). Their application to examine type of mortality
from breast cancer or other causes may be viewed as straight-
forward, in the sense that good patient follow-up may produce
specific end-points. We have used this technique (Fish et al, 1998)
to examine the effects of covariates on the type of death and time
to death for this same group of primary invasive breast cancer
patients. We found that age was associated with non-breast cancer
death; older patients had a greater tendency to die of other causes.
Meanwhile, patients with larger tumours were more likely to die
from breast cancer. A patient with a high PgR assay value or who
had no lymph node involvement was more likely to live longer,
without any specific tendency to die either from breast cancer or
another cause.
BMDP software provides a simple way of performing competing
risks analyses, with the insertion of the statement ‘COMP = CRSK’
in the regression paragraph of the Survival Analysis program, 2L.
Both SAS (SAS, 1988) and S-plus (S-plus, 1991) have programs
which fit the accelerated failure time (survival) models; a user may
specify the models that should be fit to test the competing risks
hypotheses. Allison (1995) describes the process for SAS.
The BMDP software that we used utilizes the model proposed
and demonstrated by Lagokos for lung cancer patients (Lagakos,
1978) who could have recurred locally or distantly, or be free of
disease (‘censored’) at the time of investigation. It provides a
systematic framework for examining the effects of covariates.
There are three hierarchical hypotheses tested for each covariate:
(1) the covariate has no effect on type of first recurrence and time
to first recurrence; (2) the covariate has no effect on type of first
recurrence; (3) the covariate has no effect on time of first recur-
rence, given it has no effect on type of first recurrence.
The interpretation of our results requires a short discussion at
this point. Hierarchical step (2) tests whether there is evidence that
the parameters for local, regional and distant recurrence are signi-
ficantly different. If a test is significant, then one might examine
that factor’s effect on time to recurrence, by particular type of
recurrence. If not, then the overall effect of the covariate on time to
first recurrence, of any type, is tested in step (3). The direction of a
factor’s effect may be different, although not significantly different
(P ≤ 0.05), for one type of recurrence from the others (e.g. see
Figure 2 for all ages of patients, where P = 0.06 for the test of
differences by recurrence type and where the direction of associa-
tion between age and regional recurrence is opposite to that for age
with local or distant recurrence); in this case, the overall effect on
time to first recurrence, regardless of type, is examined in step (3).
As well, a particular factor may not have a significant effect on a
type of recurrence (e.g. see Figure 2 for all ages of patients, the
effect of tumour size on regional recurrence is not significant,
although it is for local and distant recurrence); again, in this
instance, the overall effect on time to first recurrence, regardless of
type, will be examined. The complexity of these results, and need
for sound clinical interpretation, lead to reporting the full details
by type of recurrence, rather than the global test results based on
statistical significance.
The log-normal model was chosen for our competing risks
analyses because this model choice is well-supported for breast
cancer data (Chapman et al, 1996; Gamel et al, 1994, 1995;
Rutqvist et al, 1984). The underlying assumption for a log-normal
model is that, after a certain point in time, the annual risk of breast
cancer recurrence or death will decrease. It would be fairly well
accepted from clinical practice that after 3, 5 or 10 years this 
does happen. Veronesi’s data (Veronesi, 1995) demonstrate this
decrease in a competing risks context.
For all patients, we found that only adjuvant radiation differen-
tially affected the type of first recurrence. Gelman et al (1990)
showed that analytic assumptions about unobtainable recurrence
information could lead to difficulties ascertaining whether
adjuvant radiation was a beneficial adjunct for the local control of
breast cancer, and advocated the use of competing risks to assess
the effects of factors. In this context, we confirm with the
competing risks analyses the expected clinical importance of
adjuvant radiotherapy in prolonging disease-free time for local
recurrence; there was no substantial benefit from adjuvant
radiotherapy to these patients for regional or distant metastasis.
Adjuvant chemotherapy was associated with increased disease-
free time for both local and distant recurrence; the latter is
expected clinically, and the former may be attributed to a lack of
independence between local and distant recurrence. There was no
attributable benefit from adjuvant chemotherapy for regional
recurrence.
Overall, older age was associated with increased disease-free
time. The non-significant decrease in time to regional recurrence
for older patients may reflect a tendency for fewer older women to
have received an axillary dissection, and to have needed a delayed
axillary dissection outside the primary surgery period (Fish et al,
1998). Veronesi et al (1995) found that a patient’s age was an
important predictor of local and, to a lesser extent, distant
recurrence. We found strong evidence that age was an important
predictor for both local and distant recurrence.
We found across all ages of patients that there was significant
indication that nodal status and tumour size were predictors of
both local and distant recurrence; however, for patients 65 or older,
tumour size appeared to be a better predictor of distant, than local
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recurrence while nodal status was a better predictor of local, than
distant recurrence. Veronesi et al (1995) observed that tumour size
and nodal involvement were important predictors of distant
recurrence, but not local recurrence. Any differences between 
our results and those of Veronesi may be attributed easily to our
heterogeneous patient group, lower use of adjuvant radiation, and
the consideration of fewer factors. The results of more standard
single end-point investigations with a more extensive group of
factors and non-competing risks have been reported elsewhere
(Chapman et al, 1996, for local recurrence; Pritchard et al, 1993,
for distant recurrence).
For the whole group of patients, there were five factors with
significant associations with type or time to first recurrence. Only
adjuvant radiotherapy was associated with a single type of
recurrence: local. Age, nodal status, tumour size and adjuvant
chemotherapy all had significant associations across all types of
first recurrence, and in particular with time to recurrence for both
local and distant metastasis. This suggests a potential lack of inde-
pendence in these two end-points which many clinicians might not
expect.
If distant recurrence was used as a surrogate end-point for
mortality, there would only have been partial concordance at this
assessment with the competing risks of death results for these
same patients (Fish et al, 1998): the factors with significant associ-
ations with death were age, tumour size, nodal status and PgR.
The ability to assess covariate effects for a particular type of
event is related to the event rate. In this instance, only 21 of the
231 events were due to regional recurrence; this undoubtedly
affected the ability to observe significant covariate effects.
However, in this instance, the low rate of regional recurrence,
especially for the 169 Nx, clinically node negative, patients, is
itself an important result; this has been analysed and discussed in
depth elsewhere (Fish et al, 1998). It should be noted here that
most of the Nx patients did not receive adjuvant radiotherapy, but
there was a predominance of elderly in this group. Additionally,
tumours tended to be small; mammography has been used
routinely at our institution for more than three decades.
In conclusion, we found, as both Gelman et al (1990) and
Veronesi et al (1995) did, that it is important to assess the effects of
competing types of recurrence for breast cancer patients. Factors
may differentially affect the type of recurrence, and the standard
assumption of independence may not be appropriate. The avail-
ability of commercial packages which can be used to perform
competing risks analyses facilitates the use of this approach.
We demonstrated this methodology for traditional factors
obtained for a cohort of patients who have long follow-up. The
ability to assess simultaneously the effects of new covariates on
different types of recurrence will expedite investigations of the
relevance for and biologic activity of new prognostic factors.
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